# Genetic Interactions Explain Variance in Cingulate Amyloid Burden: An AV-45 PET Genome-Wide Association and Interaction Study in the ADNI Cohort

**Authors:** Jin Li, Qiushi Zhang, Feng Chen, Jingwen Yan, Sungeun Kim, Lei Wang, Weixing Feng, Andrew J. Saykin, Hong Liang, Li Shen

PMC · DOI: 10.1155/2015/647389 · BioMed Research International · 2015-09-03

## TL;DR

This study explores how gene interactions influence amyloid buildup in the brain, a key sign of Alzheimer's disease, using brain imaging and genetic data from patients.

## Contribution

The study introduces a novel approach combining genome-wide association and interaction analyses to uncover gene interactions linked to amyloid burden in Alzheimer's.

## Key findings

- Genetic main effects near APOE, APOC1, and TOMM40 were confirmed as significant.
- Eight novel SNP-SNP interactions were identified that could explain amyloid burden variability.
- The findings suggest that gene interactions may help explain missing heritability in Alzheimer's.

## Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder. Using discrete disease status as the phenotype and computing statistics at the single marker level may not be able to address the underlying biological interactions that contribute to disease mechanism and may contribute to the issue of “missing heritability.” We performed a genome-wide association study (GWAS) and a genome-wide interaction study (GWIS) of an amyloid imaging phenotype, using the data from Alzheimer's Disease Neuroimaging Initiative. We investigated the genetic main effects and interaction effects on cingulate amyloid-beta (Aβ) load in an effort to better understand the genetic etiology of Aβ deposition that is a widely studied AD biomarker. PLINK was used in the single marker GWAS, and INTERSNP was used to perform the two-marker GWIS, focusing only on SNPs with p ≤ 0.01 for the GWAS analysis. Age, sex, and diagnosis were used as covariates in both analyses. Corrected p values using the Bonferroni method were reported. The GWAS analysis revealed significant hits within or proximal to APOE, APOC1, and TOMM40 genes, which were previously implicated in AD. The GWIS analysis yielded 8 novel SNP-SNP interaction findings that warrant replication and further investigation.

## Linked entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348], APOC1 (apolipoprotein C1) [NCBI Gene 341], TOMM40 (translocase of outer mitochondrial membrane 40) [NCBI Gene 10452]
- **Diseases:** Alzheimer's disease (MONDO:0004975)

## Full-text entities

- **Genes:** LINC01913 (long intergenic non-protein coding RNA 1913) [NCBI Gene 388942], CR1 (complement C3b/C4b receptor 1 (Knops blood group)) [NCBI Gene 1378] {aka C3BR, C4BR, CD35, KN}, MAGI2 (membrane associated guanylate kinase, WW and PDZ domain containing 2) [NCBI Gene 9863] {aka ACVRIP1, AIP-1, AIP1, ARIP1, MAGI-2, NPHS15}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, CHR [NCBI Gene 1125], MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, CD33 (CD33 molecule) [NCBI Gene 945] {aka CD33rSiglec, SIGLEC-3, SIGLEC3, p67}, RWDD4 (RWD domain containing 4) [NCBI Gene 201965] {aka FAM28A, RWDD4A}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, BIN1 (bridging integrator 1) [NCBI Gene 274] {aka AMPH2, AMPHL, CNM2, SH3P9}, BCHE (butyrylcholinesterase) [NCBI Gene 590] {aka BCHED, CHE1, CHE2, E1}, TYRP1 (tyrosinase related protein 1) [NCBI Gene 7306] {aka CAS2, CATB, GP75, OCA3, TRP, TRP1}, CD2AP (CD2 associated protein) [NCBI Gene 23607] {aka CMS}, ABCA7 (ATP binding cassette subfamily A member 7) [NCBI Gene 10347] {aka ABCA-SSN, ABCX, AD9}, CLU (clusterin) [NCBI Gene 1191] {aka AAG4, APO-J, APOJ, CLI, CLU1, CLU2}, APOC1 (apolipoprotein C1) [NCBI Gene 341] {aka APOC1B, Apo-CI, ApoC-I, apo-CIB, apoC-IB}, MS4A6A (membrane spanning 4-domains A6A) [NCBI Gene 64231] {aka 4SPAN3, 4SPAN3.2, CD20L3, CDA01, MS4A6, MST090}, TACC2 (transforming acidic coiled-coil containing protein 2) [NCBI Gene 10579] {aka AZU-1, ECTACC}, HNF4A (hepatocyte nuclear factor 4 alpha) [NCBI Gene 3172] {aka FRTS4, HNF4, HNF4a7, HNF4a8, HNF4a9, HNF4alpha}, EPHA1 (EPH receptor A1) [NCBI Gene 2041] {aka EPH, EPHT, EPHT1}, BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}, TOMM40 (translocase of outer mitochondrial membrane 40) [NCBI Gene 10452] {aka C19orf1, D19S1177E, PER-EC1, PEREC1, TOM40}, MS4A4E (membrane spanning 4-domains A4E) [NCBI Gene 643680], IGFBP3 (insulin like growth factor binding protein 3) [NCBI Gene 3486] {aka BP-53, IBP-3, IBP3, IGFBP-3}, PICALM (phosphatidylinositol binding clathrin assembly protein) [NCBI Gene 8301] {aka CALM, CLTH, LAP}, FHIT (fragile histidine triad diadenosine triphosphatase) [NCBI Gene 2272] {aka AP3Aase, FRA3B}, CLSTN2 (calsyntenin 2) [NCBI Gene 64084] {aka ALC-GAMMA, CDHR13, CS2, CSTN2, alcagamma}, PRNP (prion protein (Kanno blood group)) [NCBI Gene 5621] {aka ASCR, AltPrP, CD230, CJD, GSS, KURU}
- **Diseases:** neurodegenerative disorder (MESH:D019636), dementia (MESH:D003704), Amyloid (MESH:C000718787), amyloid deposition (MESH:D058225), brain atrophy (MESH:C566985), EMCI (MESH:D060825), glucose hypometabolism (MESH:D018149), HC (MESH:D000067329), AD (MESH:D000544), cingulate amyloid (MESH:D017034), cognitive impairment (MESH:D003072), AV-45 (OMIM:616669), neurofibrillary tangles (MESH:D055956), hippocampal atrophy (MESH:D001284)
- **Chemicals:** cholesterol (MESH:D002784), Pittsburgh compound-B (MESH:C475519), 18F-AV-45 (MESH:C545186), PiB (MESH:C069442), N-methyl-[11C]2-(40-methylaminophenyl)-6-hydroxybenzothiazole (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs13426621, rs13056151, rs2326536, rs7916162, rs2194938, rs6854047, rs4420638, rs2295873, rs17594541, rs16939265, rs2295874, rs7644138, rs10504164, rs16936424, rs7037332, rs7794838

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4573220/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4573220/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC4573220/full.md

---
Source: https://tomesphere.com/paper/PMC4573220